Neil Brewis

Neil Brewis

Auto-generated profile, based on publicly available information

Neil Brewis

F-Star Therapeutics, Babraham Research Campus, Cambridgeshire, United Kingdom. 3

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MLMatthew A. Lakins
Matthew A. Lakins
AKAlexander Koers
Alexander Koers
RGRaffaella Giambalvo
Raffaella Giambalvo
JMJose Munoz-Olaya
Jose Munoz-Olaya
RHRobert Hughes
Robert Hughes
NBNeil Brewis
Neil Brewis
Purpose: With the increased prevalence in checkpoint therapy resistance, there remains a significant unmet need for additional therapies for relapsing or refractory cancer patients. We have developed FS222, a bispecific tetravalent antibody targeting CD137 and PD-L1 to induce T cell activation to eradicate tumours without the current toxicity and efficacy limitations seen clinically. Experimental Design: A bispecific antibody (FS222) was developed by engineering CD137 binding sites into the Fc region of a PD-L1 IgG1 mAb. T cell activation by FS222 was investigated using multiple in vitro assays. The anti-tumour efficacy, survival benefit, pharmacodynamics and liver pharmacology of a murine surrogate molecule were assessed in syngeneic mouse tumour models. Toxicology and the pharmacokinetic/pharmacodynamic profile of FS222 was investigated in a non-human primate dose-range finding study. Results: We demonstrated simultaneous binding of CD137 and PD-L1 and showed potent T cell activation across CD8+ T cell activation assays in a PD-L1-dependent manner with FS222. FS222 also activated T cells in a human primary mixed lymphocyte reaction assay, with greater potency than the monospecific mAb combination. FS222 showed no signs of liver toxicity up to 30 mg/kg in a non-human primate dose-range finding study. A surrogate molecule caused significant tumour growth inhibition and survival benefit, concomitant with CD8+ T cell activation, in CT26 and MC38 syngeneic mouse tumour models. Conclusions: By targeting CD137 agonism to areas of PD-L1 expression, predominantly found in the tumour microenvironment, FS222 has the potential to leverage a focused, potent and safe immune response augmenting the PD-(L)1 axis blockade.

9 November 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
TYTimothy A. Yap
Timothy A. Yap
PLPatricia M. LoRusso
Patricia M. LoRusso
DWDeborah Wong
Deborah Wong
SHSiwen Hu-Lieskovan
Siwen Hu-Lieskovan
KPKyriakos P. Papadopoulos
Kyriakos P. Papadopoulos
MMMichelle Morrow
Michelle Morrow
Purpose: This phase 1 study (NCT03440437) evaluated the safety, tolerability, pharmacokinetics (PK), and activity of FS118, a bispecific antibody–targeting LAG-3 and PD-L1, in patients with advanced cancer resistant to anti–PD-(L)1 therapy. Patients and Methods: Patients with solid tumors, refractory to anti–PD-(L)1–based therapy, received intravenous FS118 weekly with an accelerated dose titration design (800 μg to 0.3 mg/kg) followed by 3+3 ascending dose expansion (1 to 20 mg/kg). Primary objectives were safety, tolerability, and PK. Additional endpoints included antitumor activity, immunogenicity, and pharmacodynamics. Results: Forty-three patients with a median of three prior regimens in the locally advanced/metastatic setting, including at least one anti–PD-(L)1 regimen, received FS118 monotherapy. FS118 was well tolerated, with no serious adverse events relating to FS118 reported. No dose-limiting toxicities (DLT) were observed, and an MTD was not reached. The recommended phase 2 dose of FS118 was established as 10 mg/kg weekly. The terminal half-life was 3.9 days. Immunogenicity was transient. Pharmacodynamic activity was prolonged throughout dosing as demonstrated by sustained elevation of soluble LAG-3 and increased peripheral effector cells. The overall disease control rate (DCR) was 46.5%; this disease control was observed as stable disease, except for one late partial response. Disease control of 54.8% was observed in patients receiving 1 mg/kg or greater who had acquired resistance to PD-(L)1–targeted therapy. Conclusions: FS118 was well tolerated with no DLTs observed up to and including 20 mg/kg QW. Further studies are warranted to determine clinical benefit in patients who have become refractory to anti–PD-(L)1 therapy. See related commentary by Karapetyan and Luke, p. 835

1 August 2024 in Cancer Research Communications
Verified
Journal Article
Open access
CICharlotte J. Imianowski
Charlotte J. Imianowski
PKPaula Kuo
Paula Kuo
SWSarah K. Whiteside
Sarah K. Whiteside
TLTeresa von Linde
Teresa von Linde
AWAlexander J. Wesolowski
Alexander J. Wesolowski
RRRahul Roychoudhuri
Rahul Roychoudhuri
Regulatory T cells (Treg) are highly enriched within many tumors and suppress immune responses to cancer. There is intense interest in reprogramming Tregs to contribute to antitumor immunity. OX40 and CD137 are expressed highly on Tregs, activated and memory T cells, and NK cells. In this study, using a novel bispecific antibody targeting mouse OX40 and CD137 (FS120m), we show that OX40/CD137 bispecific agonism induces potent antitumor immunity partially dependent upon IFNγ production by functionally reprogrammed Tregs. Treatment of tumor-bearing animals with OX40/CD137 bispecific agonists reprograms Tregs into both fragile Foxp3+ IFNγ+ Tregs with decreased suppressive function and lineage-instable Foxp3− IFNγ+ ex-Tregs. Treg fragility is partially driven by IFNγ signaling, whereas Treg instability is associated with reduced IL2 responsiveness upon treatment with OX40/CD137 bispecific agonists. Importantly, conditional deletion of Ifng in Foxp3+ Tregs and their progeny partially reverses the antitumor efficacy of OX40/CD137 bispecific agonist therapy, revealing that reprogramming of Tregs into IFNγ-producing cells contributes to the anti-tumor efficacy of OX40/CD137 bispecific agonists. These findings provide insights into mechanisms by which bispecific agonist therapies targeting costimulatory receptors highly expressed by Tregs potentiate antitumor immunity in mouse models. Significance: The bispecific antibody FS120, an immunotherapy currently being tested in the clinic, partially functions by inducing anti-tumor activity of Tregs, which results in tumor rejection.

13 December 2023 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
CXChunxiao Xu
Chunxiao Xu
XZXueyuan Zhou
Xueyuan Zhou
LWLindsay Webb
Lindsay Webb
SYSireesha Yalavarthi
Sireesha Yalavarthi
WZWenxin Zheng
Wenxin Zheng
LHLaura Helming
Laura Helming
The costimulatory receptor CD137 (also known as TNFRSF9 or 4-1BB) sustains effective cytotoxic T-cell responses. Agonistic anti-CD137 cancer immunotherapies are being investigated in clinical trials. Development of the first-generation CD137-agonist monotherapies utomilumab and urelumab was unsuccessful due to low antitumor efficacy mediated by the epitope recognized on CD137 or hepatotoxicity mediated by Fcγ receptors (FcγR) ligand–dependent CD137 activation, respectively. M9657 was engineered as a tetravalent bispecific antibody (mAb2) in a human IgG1 backbone with LALA mutations to reduce binding to FCγRs. Here, we report that M9657 selectively binds to mesothelin (MSLN) and CD137 with similar affinity in humans and cynomolgus monkeys. In a cellular functional assay, M9657 enhanced CD8+ T cell–mediated cytotoxicity and cytokine release in the presence of tumor cells, which was dependent on both MSLN expression and T-cell receptor/CD3 activation. Both FS122m, a murine surrogate with the same protein structure as M9657, and chimeric M9657, a modified M9657 antibody with the Fab portion replaced with an anti-murine MSLN motif, demonstrated in vivo antitumor efficacy against various tumors in wild-type and human CD137 knock-in mice, and this was accompanied by activated CD8+ T-cell infiltration in the tumor microenvironment. The antitumor immunity of M9657 and FS122m depended on MSLN expression density and the mAb2 structure. Compared with 3H3, a murine surrogate of urelumab, FS122m and chimeric M9657 displayed significantly lower on-target/off-tumor toxicity. Taken together, M9657 exhibits a promising profile for development as a tumor-targeting immune agonist with potent anticancer activity without systemic immune activation and associated hepatotoxicity.

12 August 2024
Verified
Other
Open access
CICharlotte J. Imianowski
Charlotte J. Imianowski
PKPaula Kuo
Paula Kuo
SWSarah K. Whiteside
Sarah K. Whiteside
TLTeresa von Linde
Teresa von Linde
AWAlexander J. Wesolowski
Alexander J. Wesolowski
RRRahul Roychoudhuri
Rahul Roychoudhuri
Regulatory T cells (Treg) are highly enriched within many tumors and suppress immune responses to cancer. There is intense interest in reprogramming Tregs to contribute to antitumor immunity. OX40 and CD137 are expressed highly on Tregs, activated and memory T cells, and NK cells. In this study, using a novel bispecific antibody targeting mouse OX40 and CD137 (FS120m), we show that OX40/CD137 bispecific agonism induces potent antitumor immunity partially dependent upon IFNγ production by functionally reprogrammed Tregs. Treatment of tumor-bearing animals with OX40/CD137 bispecific agonists reprograms Tregs into both fragile Foxp3+ IFNγ+ Tregs with decreased suppressive function and lineage-instable Foxp3− IFNγ+ ex-Tregs. Treg fragility is partially driven by IFNγ signaling, whereas Treg instability is associated with reduced IL2 responsiveness upon treatment with OX40/CD137 bispecific agonists. Importantly, conditional deletion of Ifng in Foxp3+ Tregs and their progeny partially reverses the antitumor efficacy of OX40/CD137 bispecific agonist therapy, revealing that reprogramming of Tregs into IFNγ-producing cells contributes to the anti-tumor efficacy of OX40/CD137 bispecific agonists. These findings provide insights into mechanisms by which bispecific agonist therapies targeting costimulatory receptors highly expressed by Tregs potentiate antitumor immunity in mouse models.Significance:The bispecific antibody FS120, an immunotherapy currently being tested in the clinic, partially functions by inducing anti-tumor activity of Tregs, which results in tumor rejection.

12 August 2024
Verified
Other
Open access
CICharlotte J. Imianowski
Charlotte J. Imianowski
PKPaula Kuo
Paula Kuo
SWSarah K. Whiteside
Sarah K. Whiteside
TLTeresa von Linde
Teresa von Linde
AWAlexander J. Wesolowski
Alexander J. Wesolowski
RRRahul Roychoudhuri
Rahul Roychoudhuri
Supplementary Figure 2: T cell populations in the spleen and tumor of FS120m treated mice. (A) Percentages of indicated T cell populations in the tumors of mice treated with FS120m or control antibodies. (B) Percentages of indicated T cell populations in the spleens of mice treated with FS120m or control antibodies. (C) Absolute counts of exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m treated animals. (D) Absolute counts of IFN-γ producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. (E) Absolute counts of TNF producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. * P ≤ 0.05, ** P ≤ 0.01. Student’s t test. Bars and error are mean and s.e.m.